advertisement
Abstract #121595 Published in IGR 25-1
Topical insulin to treat a conjunctival defect after glaucoma surgery: A case report
Burgos-Blasco B; Yeung SN; Docherty G; Iovieno AAmerican journal of ophthalmology case reports 2024; 36: 102127
PURPOSE: Insulin has been postulated as a novel and effective treatment for re-epithelialization of the ocular surface and different pathologies have been suggested as possible indications. OBSERVATIONS: A 69-year-old diabetic male was referred for a left non-healing conjunctival epithelial defect over the superotemporal scleral patch used in the placement of the Ahmed ClearPath. In the left eye, he was on latanoprost/timolol once daily, prednisolone 1 % once daily and tobramycin/dexamethasone ointment at night. Best-corrected visual acuity was 20/20 in the right eye and 20/25 in the left eye. Slit lamp examination of the left eye showed patches of avascular scleral tissue nasally and superiorly, conjunctival and Tenon defect over a thin avascular scleral patch graft. The patient was started on Humulin insulin 1UI/mL 6 times a day and the defect healed after 3 months of treatment. CONCLUSIONS AND IMPORTANCE: Insulin eye drops may be used in the treatment of chronic conjunctival epithelial defects following implantation of glaucoma drainage devices.
Department of Ophthalmology and Visual Sciences, University of British Columbia, Vancouver, Canada.
Full article